Jefferies Financial Group restated their hold rating on shares of Indivior (LON:INDV) in a research note published on Friday morning, Stock Target Advisor reports.
Separately, Citigroup reaffirmed a neutral rating on shares of Indivior in a report on Thursday, November 7th.
Shares of INDV stock traded down GBX 3.73 ($0.05) during mid-day trading on Friday, hitting GBX 37.61 ($0.49). 3,121,561 shares of the stock were exchanged, compared to its average volume of 2,440,000. The stock’s fifty day simple moving average is GBX 45.82 and its two-hundred day simple moving average is GBX 48.84. The stock has a market capitalization of $274.83 million and a price-to-earnings ratio of 1.30. Indivior has a 12-month low of GBX 20.98 ($0.27) and a 12-month high of GBX 223.50 ($2.92). The company has a debt-to-equity ratio of 115.87, a quick ratio of 1.97 and a current ratio of 2.09.
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Further Reading: Are FAANG stocks a good investment?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.